INDV Bounce Up Signal

BUY Bounce Up Stopped out
Pharmaceuticals · Bull Market
★★★★★
6/0 Quality
Entry
$34.66
Stop Loss
$33.19
TP1
$38.34
TP2
$40.55
R:R
2.50

Analyst vs AI Verdict

Wall Street
90.0% Buy Rating
3
Str.Buy
6
Buy
1
Hold
0
Sell
0
Str.Sell
10 analysts · Sept. 1, 2026
AI Expert Panel

Price Chart

Fundamentals Trend

Metric 2025-09-022025-10-022025-11-032025-12-032026-01-022026-08-10
ROE (TTM) 135.4%135.4%135.4%159.1%159.1%159.1%
P/E (TTM) ———33.9635.8412.90
Net Margin -4.4%-4.4%-4.4%10.6%10.6%26.6%
Gross Margin 147.9%147.9%147.9%85.5%85.5%82.0%
D/E Ratio 2790.002790.002790.002790.002790.00—
Current Ratio 0.880.880.880.960.960.84

Company Summary

Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

View full stock profile →

More Signals for INDV

View all →

Related News

View all →

Disclaimer: This is an automated trading signal generated by AI analysis. It is not financial advice. Always do your own research before making investment decisions. Past performance does not guarantee future results.